Gilman Hill Asset Management’s Biogen BIIB Stock Holding History

Gilman Hill Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-687	Closed	-$233K	–	171
2014 Q4	$233K	Buy	687 +12	+2%	+$3.88K	0.12%	134
2014 Q3	$223K	Sell	675 -175	-21%	-$57.7K	0.12%	134
2014 Q2	$268K	Buy	850 +50	+6%	+$15K	0.14%	122
2014 Q1	$245K	Hold	800	–	–	0.14%	113
2013 Q4	$224K	Buy	+800	New	+$207K	0.15%	105

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Gilman Hill Asset Management's BIIB Position: Q1 2015 in Review

Gilman Hill Asset Management sold out of Biogen (BIIB) in Q1 2015, closing a stake of 687 shares — an estimated $233K sold.

Gilman Hill Asset Management first reported a position in BIIB in Q4 2013 and held it in 5 quarters. The position peaked at $268K in Q2 2014. 966 funds tracked by Wall St. Rank hold BIIB as of Q1 2015.

Gilman Hill Asset Management reported no remaining Biogen position as of Q1 2015 after selling out during the quarter.
Gilman Hill Asset Management sold 687 Biogen shares in Q1 2015, an estimated $233K.
Gilman Hill Asset Management first reported a position in Biogen in Q4 2013 and held it in 5 quarters.
Gilman Hill Asset Management's Biogen position peaked at $268K in Q2 2014.
966 funds tracked by Wall St. Rank held Biogen as of Q1 2015.

Based on Gilman Hill Asset Management's 13F filing for Q1 2015, filed 28 Apr 2015.